Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 11/20 | 0.97 |
| ▸ | DRD3 | P35462 | 10/20 | 0.71 |
| ▸ | DRD4 | P21917 | 8/20 | 0.68 |
| ▸ | DRD1 | P21728 | 6/20 | 0.68 |
| ▸ | DRD5 | P21918 | 6/20 | 0.68 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.67 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.67 |
| ▸ | PRCP | P42785 | 1/20 | 0.67 |
| ▸ | EBP | Q15125 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2861859 | 0.99 | DRD2 (1.00) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL2861863 | 0.99 | DRD2 (1.00) | DRD2DRD3DRD4DRD1DRD5 | |
| Hydrochloric Acid SCHEMBL7317357 | 0.97 | DRD2 (0.97) | DRD2DRD3DRD4DRD1DRD5 | |
| Bromide SCHEMBL7314081 | 0.97 | DRD2 (0.97) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL11270511 | 0.95 | DRD2 (0.93) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL7353948 | 0.91 | DRD2 (0.86) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL7314494 | 0.91 | DRD2 (0.87) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL7315588 | 0.90 | DRD2 (0.84) | DRD2DRD3DRD4DRD1DRD5 | |
| Hydrochloric Acid SCHEMBL7316558 | 0.90 | DRD2 (0.84) | DRD2DRD3DRD4DRD1DRD5 | |
| Preclamol SCHEMBL10510876 | 0.90 | DRD2 (0.83) | DRD2DRD3DRD4DRD1DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6596724-B2 | Used in promoting weight loss and treating eating disorders | BRISTOL-MYERS SQUIBB COMPANY | 2003-07-22 | — | — | US | disclosed |
| US-20020013323-A1 | Oxadiazole and thiadiazole derivatives of dihydropyridine NPY antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2002-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013323-A1 | Oxadiazole and thiadiazole derivatives of dihydropyridine NPY antagonists | NPY1R, NPY2R, NPY5R | DRD2 52/4885DRD3 63/4885DRD4 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.